Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...

Shares of Sun Pharmaceutical Industries rose more than 3 per cent following ICICI Securities' upgrade of the stock to a 'Buy' ...

The brokerage firm Motilal Oswal had a ‘Buy call on three stocks on March 11. It has picked Sun Pharma after Checkpoint ...

Five things you need to know in local business news to start your workday, including how Monday's stock market rout shaved $21 billion off five Massachusetts companies, plus more MGB layoffs, a ...

Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics ...

Brokerages have revealed a favourable outlook for the stock with the acquisition expected to be completed by the second half of 2025.

Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains 'Buy' with 22% upside potential. Read ...

Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.50. The rise is despite the ...

Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology ...

Sun Pharma shares rose like the sun in the intraday trade on Tuesday, as the company shares surged by over 2 per cent in the ...

ICICI Securities is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 1895 in its research report dated March 11, 2025.